Curbing industry sponsor's incentive to design post-approval trials that are suboptimal for informing prescribers but more likely than optimal designs to yield favorable results. [electronic resource]
Producer: 20080411Description: 969-1049 p. digitalISSN:- 0586-5964
- Clinical Protocols
- Clinical Trials, Phase IV as Topic -- economics
- Complementary Therapies
- Cost-Benefit Analysis
- Dose-Response Relationship, Drug
- Drug Approval
- Drug Industry -- economics
- Drug-Related Side Effects and Adverse Reactions
- Epidemiologic Factors
- Financial Support
- Formularies as Topic
- Government Regulation
- Humans
- Information Services
- Insurance Coverage
- Insurance, Pharmaceutical Services
- Motivation
- Organizational Policy
- Outcome and Process Assessment, Health Care
- Patient Selection
- Practice Patterns, Physicians'
- Private Sector
- Product Surveillance, Postmarketing
- Public Sector
- Publication Bias
- Quality Control
- Racial Groups
- Research Design
- Severity of Illness Index
- Time Factors
- United States
- United States Food and Drug Administration
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.